Amylyx, faced with longer FDA path for promising ALS drug, gets major cash infusion

Amylyx Pharmaceuticals, a small biotech developing a promising experimental medicine for ALS, has raised $135 million from a group of venture capital firms to fund late-stage clinical testing and preparations for a potential launch should regulators in Canada and Europe approve the drug.